Contraception
Conditions
Keywords
Male contraception, testosterone, acyline
Brief summary
The purpose of this research study is to help in the development of male contraception (birth control).
Detailed description
The objective is to conduct a male contraceptive trial in which we will evaluate the suppressive effects of acyline when administered in combination with Testosterone (T) and the progestin depo-medroxyprogesterone acetate (DMPA). We will be administering combinations of three drugs: Testosterone (T) by gel, Depot Medroxyprogesterone acetate (DMPA) and Acyline to see their effects on sperm production. The T/DMPA/Acyline combination will allow us to determine if the more rapid and complete gonadotropin suppression mediated by the early addition of a GnRH antagonist will accelerate and enhance suppression of spermatogenesis. In prior studies with testosterone and DMPA these drug, which are hormones, have been found to be safe, and to reversibly suppress sperm counts to zero in about 80% of men. We hope to improve this to 100% of men by adding another drug, Acyline. Acyline is an GnRH antagonist which blocks the release of LH and FSH from the pituitary. DMPA is approved by the FDA for use as a female contraceptive. The endpoint will be suppression of spermatogenesis to zero (azoospermia) by the end of the treatment phase.
Interventions
DRUGTestosterone Gel
Testosterone Gel (10 g daily
DRUGAcyline
Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
DMPA (injected into muscle) Day 0 & month 3
Sponsors
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CONRAD
University of Washington
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Males between 18-55 * In good general health * With normal sperm counts * Willing to use an acceptable form of contraception
Exclusion criteria
* Men in poor health * Significant chronic or acute medical illness * Skin conditions that might interfere with or be exacerbated by testosterone gel * Known history of alcohol, illicit drug or anabolic steroid abuse * Abnormal reproductive function * Participation in a long-term male contraceptive study within past three months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary biological end points in this trial will be suppression of spermatogenesis and gonadotropins while monitoring for any adverse changes in lipid metabolism, sexual side effects or in general health | One year |
Secondary
| Measure | Time frame |
|---|---|
| Regimen acceptability, sexual function, glucose tolerance, intratesticular hormone levels | One year |
Countries
United States
Outcome results
None listed